以模型为基础优化塔克罗利斯的剂量,用于与伊特拉科纳同时给日本肺移植接受者
Ren Takahashi1, Kotaro Itohara1,2, Shunsaku Nakagawa1
1Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
Therapeutic drug monitoring
|August 8, 2024
概括
这项研究开发了一种用于日本肺移植患者服用伊特拉可纳的塔克罗利斯的剂量方法. 当伊特拉科纳开始使用时,剂量应减少60%,以保持药物标水平.
科学领域:
- 药理学 药理学是指药理学的学科.
- 移植医学 移植医学
- 药物相互作用 药物相互作用
背景情况:
- 塔克罗利马斯是肺移植后的重要免疫抑制剂.
- 伊特拉科纳经常同时使用,以预防真菌感染并提高塔克罗利斯水平.
- 有限的数据存在于日本肺移植接受者中塔克罗利斯的药理动力学,特别是关于伊特拉科纳的影响.
研究的目的:
- 在日本肺移植接受者中分析塔克罗利斯的药理动力学.
- 为了评估伊特拉科纳对塔克罗利斯药理动学的影响.
- 在启动伊特拉可纳时建立一个优化的塔克罗利斯剂量策略.
主要方法:
- 使用非线性混合效应建模的群体药理动力学分析.
- 包括日本肺移植接受者与测量塔克罗利斯和伊特拉可纳度 (2017年1月至2019年12月).
- 确定影响塔克罗利斯药理动力学和药物相互作用的共同变量.
主要成果:
- 分析了来自43名患者的1693个塔克罗利斯和85个伊特拉可纳度.
- 手术后的一天,白蛋白水平和给药途径是显著的共同变量.
- 伊特拉科纳的度依赖抑制准确地预测了药物相互作用,在开始时需要减少60%的塔克罗利斯剂量.
结论:
- 这是第一个关于肺移植受体中塔克罗利斯-伊特拉科纳相互作用的群体药理学研究.
- 这些发现为调整伊特拉可纳与伊特拉可纳联合使用时的初始塔克罗利斯剂量提供了关键指导.
- 开发了一种优化的剂量方法,以在同时使用伊特拉科纳时控制塔克罗利斯水平.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
01:15Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
01:29Pulmonary Tuberculosis I
227
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
227
01:28Pulmonary Tuberculosis V
176
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
176
01:11Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K